Document Type
Article
Publication Date
1-6-2023
Original Citation
Perova Z,
Martinez M,
Mandloi T,
Gomez F,
Halmagyi C,
Follette A,
Mason J,
Neuhauser S,
Begley DA,
Krupke D,
Bult C,
Parkinson H,
Groza T.
PDCM Finder: an open global research platform for patient-derived cancer models. Nucleic Acids Res. 2023;51(D1):D1360–D6.
Keywords
Humans, Child, Neoplasms, Organoids, Xenograft Model Antitumor Assays
JAX Source
Nucleic Acids Res. 2023;51(D1):D1360–D6.
ISSN
1362-4962
PMID
36399494
DOI
https://doi.org/10.1093/nar/gkac1021
Grant
National Institutes of Health/National Cancer Institute [U24 CA204781, U24 CA253539 to H.P., R01 CA089713 to C.B.]. Funding for open access charge: National Institutes of Health and EMBL-EBI Core Fund (to T.G. and H.P.).
Abstract
PDCM Finder (www.cancermodels.org) is a cancer research platform that aggregates clinical, genomic and functional data from patient-derived xenografts, organoids and cell lines. It was launched in April 2022 as a successor of the PDX Finder portal, which focused solely on patient-derived xenograft models. Currently the portal has over 6200 models across 13 cancer types, including rare paediatric models (17%) and models from minority ethnic backgrounds (33%), making it the largest free to consumer and open access resource of this kind. The PDCM Finder standardises, harmonises and integrates the complex and diverse data associated with PDCMs for the cancer community and displays over 90 million data points across a variety of data types (clinical metadata, molecular and treatment-based). PDCM data is FAIR and underpins the generation and testing of new hypotheses in cancer mechanisms and personalised medicine development.
Comments
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.